Indo-Bangla Pharmaceuticals (DHA:IBP) EBITDA Margin %: 0.00% (As of . 20)


DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT15.30
View Full Analysis

What is Indo-Bangla Pharmaceuticals EBITDA Margin %?

Indo-Bangla Pharmaceuticals DHA:IBP +1.32% 32 EBITDA Margin % is 0.00% as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100. Among 955 Drug Manufacturers companies, Indo-Bangla Pharmaceuticals ranks worse than 104711.94% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Indo-Bangla Pharmaceuticals's EBITDA for the six months ended in . 20 was BDT0.00 Mil. Indo-Bangla Pharmaceuticals's Revenue for the six months ended in . 20 was BDT0.00 Mil. Therefore, Indo-Bangla Pharmaceuticals's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Indo-Bangla Pharmaceuticals  (DHA:IBP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Indo-Bangla Pharmaceuticals EBITDA Margin % Related Terms

Indo-Bangla Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals EBITDA Margin % Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
EBITDA Margin %

Indo-Bangla Pharmaceuticals Semi-Annual Data
EBITDA Margin %

DHA:IBP vs : EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indo-Bangla Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Indo-Bangla Pharmaceuticals's EBITDA Margin % falls into.


DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Indo-Bangla Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Indo-Bangla Pharmaceuticals's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indo-Bangla Pharmaceuticals and its competitors. According to the industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 955 companies in the Drug Manufacturers industry.
Is Indo-Bangla Pharmaceuticals' EBITDA Margin % too high?
Indo-Bangla Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' EBITDA Margin % compare to ?
According to the Drug Manufacturers industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 955 companies for EBITDA Margin %. This places Indo-Bangla Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indo-Bangla Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo-Bangla Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT15.30
Price